Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Product Unit Size | Cost | Quantity | Stock |
|---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Cas No. | 1258595-14-0 |
|---|---|
| Purity | ≥99% |
| Formula | C29H32F2N3O7P |
| Formula Wt. | 603.56 |
| IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
| Synonym | LHC165 |
| Appearance | Pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Expectorant.
Organosulfur found in garlic.
Triterpene; potential tyrosinase inhibitor.
Peptide; NK2 antagonist.
NSAID; COX-1/2 inhibitor.
Synthetic ITC, erysolin analog.
Recombinant protein containing Treponema pallid...
Purine (hypoxanthine) analog; xanthine oxidase ...
Carcinoembryonic antigen epitope.
Bipyridamine toxin.
Statin; HMG-CoA reductase inhibitor, potential ...
Corticosteroid
EZH2 inhibitor
Sesquiterpene lactone found in Saussurea.
Alkaloid compound originally found in Corydalis...
Cathelicidin derivative, antimicrobial peptide,...
SIRT1/2 inhibitor, indirect p53 activator.
Inhibitor of Bruton’s tyrosine kinase (BTK).<...
Endogenous peptide, involved in immune signalin...
CRM1/XPO1 inhibitor.